Trials / Terminated
TerminatedNCT05602727
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study To Evaluate The Safety And Efficacy Of MK-1942 As Adjunctive Therapy In Participants With Mild To Moderate Alzheimer's Disease Dementia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 55 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-1942 | MK-1942 oral capsule |
| DRUG | Placebo | Placebo oral capsule |
Timeline
- Start date
- 2022-12-02
- Primary completion
- 2023-09-27
- Completion
- 2023-09-27
- First posted
- 2022-11-02
- Last updated
- 2024-12-10
- Results posted
- 2024-10-15
Locations
74 sites across 11 countries: United States, Argentina, Australia, Canada, Colombia, Italy, Japan, New Zealand, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05602727. Inclusion in this directory is not an endorsement.